Flagship Pioneering

AppLovin Appoints Barbara Messing to its Board of Directors

Retrieved on: 
Tuesday, February 27, 2024

AppLovin Corporation (NASDAQ: APP) (“AppLovin”), a leading marketing platform, today announced the appointment of Barbara Messing, former Roblox Chief Marketing and Communications Officer to its Board of Directors.

Key Points: 
  • AppLovin Corporation (NASDAQ: APP) (“AppLovin”), a leading marketing platform, today announced the appointment of Barbara Messing, former Roblox Chief Marketing and Communications Officer to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240227161788/en/
    AppLovin appoints Barbara Messing, former Roblox Chief Marketing and Communications Officer to its Board of Directors.
  • “We welcome Barbara as an advisor and prominent addition to the AppLovin board,” said Adam Foroughi, Co-founder, CEO and Chairperson of AppLovin.
  • She previously served on the board of directors of Overstock.com, Inc., and the board of directors of publicly-traded XO Group, Inc., which merged with WeddingWire in December 2018.

Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Every Cure, a nonprofit on a mission to save lives by repurposing existing medicines, announced today significant funding from the Advanced Research Projects Agency for Health (ARPA-H). The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing. It will accelerate Every Cure's mission to unlock the full potential of existing drugs to treat more diseases through the development of an AI-powered platform, called ML/AI-enabled Therapeutic Repurposing In eXtended uses (MATRIX).

Key Points: 
  • The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing.
  • "I'm alive and in remission from my rare disease thanks to a repurposed drug that I discovered.
  • "Through Every Cure, we are working tirelessly to unlock the full potential of FDA-approved drugs to treat many more diseases.
  • The ARPA-H funding will enable Every Cure to:
    Develop an open-source drug repurposing database.

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.

Aurora to Honor the Best of Humanity in Los Angeles

Retrieved on: 
Wednesday, February 21, 2024

LOS ANGELES, Feb. 21, 2024 /PRNewswire/ -- The Aurora Humanitarian Initiative announced that a special series of events will be held from May 8–10, 2024 in Los Angeles, CA. The events, including the 2024 Aurora Prize Ceremony and the Human Rights and Humanitarian Forum, are being organized in partnership with The Promise Institute for Human Rights at UCLA.

Key Points: 
  • The events, including the 2024 Aurora Prize Ceremony and the Human Rights and Humanitarian Forum, are being organized in partnership with The Promise Institute for Human Rights at UCLA.
  • Dr. Esrailian, also an Emmy-nominated film producer and entrepreneur, led the efforts to establish The Promise Institute for Human Rights at UCLA in 2017.
  • "The 2024 Aurora Prize events in Los Angeles will offer guests and participants a chance to express their appreciation to those who selflessly help others in need.
  • The 2024 Aurora Prize for Awakening Humanity Laureate will be announced during the Aurora Prize Ceremony, with the Laureate selected from the Aurora Humanitarians shortlisted in September 2023.

Sail Biomedicines Appoints Kerry Benenato, Ph.D., as Chief Platform Officer

Retrieved on: 
Wednesday, February 7, 2024

Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Kerry Benenato, Ph.D., has been appointed to the position of the role of Chief Platform Officer, replacing Stuart Milstein, Ph.D., who is leaving the company to pursue other opportunities.

Key Points: 
  • Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Kerry Benenato, Ph.D., has been appointed to the position of the role of Chief Platform Officer, replacing Stuart Milstein, Ph.D., who is leaving the company to pursue other opportunities.
  • Dr. Benenato brings to Sail a storied career in the development of mRNA products and product candidates.
  • “We are delighted to welcome Kerry to Sail and its Executive Leadership Team.
  • “The potential of Sail’s platform – combining industry-leading Endless RNA™ (eRNA™) technology with uniquely programmable deployment nanoparticles, accelerated by AI – is unparalleled within the biopharma industry.

Inari Accelerates Proven SEEDesign™ Platform for Nature-Positive Agriculture with $103 Million Fundraise

Retrieved on: 
Tuesday, January 30, 2024

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Inari today announced the completion of a $103 million fundraise, bringing its cumulative equity raised to more than $575 million. The successful investment round signals confidence in Inari's ability to develop and commercialize higher-yielding seeds that require fewer resources, using AI-powered predictive design and multiplex gene editing.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Inari today announced the completion of a $103 million fundraise, bringing its cumulative equity raised to more than $575 million.
  • The company also welcomed several new investors including RCM Private Markets fund, advised by Rokos Capital Management (US) LP.
  • Hanwha Impact highlighted Inari's strong progress since their initial 2021 investment as a key reason for their increased support in this fundraise.
  • Added Stephen Berenson, Flagship Pioneering Managing Partner: "This successful fundraise reflects continued confidence in the company's ability to deliver on its nature-positive vision.

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

Retrieved on: 
Wednesday, January 17, 2024

NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024.

Key Points: 
  • NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024.
  • “NAYA is thrilled to welcome new board members with outstanding executive and entrepreneurial track records,” commented NAYA CEO Dr. Daniel Teper.
  • She is currently Executive Engagement Lead at Publicis, the 2nd largest communications group in the world, where she launched multiple brands as Chief Marketing Officer.
  • He previously held several leadership positions in corporate and business development and partnerships at Sanofi.

Valo Health Announces Changes to its Board of Directors and Leadership Team

Retrieved on: 
Tuesday, January 16, 2024

BOSTON, Jan. 16, 2024 /PRNewswire/ -- Valo Health, Inc ("Valo"), a technology company focused on utilizing large scale data and artificial intelligence ("AI") driven computation to discover and develop therapeutics, today announced the appointment of Christian Schade as the newly-created role of Executive Chairman of the Board of Directors­ and Graeme Bell as interim CEO, effective immediately.

Key Points: 
  • Schade has served as a Board Director for Valo Health since September 2023, a role he took on after joining Flagship Pioneering as Growth Partner in January 2023.
  • D., who has served as CEO of Valo Health since its launch by Flagship Pioneering in 2019 and whose last day of employment is February 2.
  • "Chris and Graeme have made tremendous contributions to Valo during their tenure, and the Board of Directors is confident they are the right leaders for Valo's future," said Paul Biondi, Chairman of the Board of Directors, Valo Health, and Executive Partner, Flagship Pioneering.
  • "The tremendously talented team at Valo and the organization's deep commitment to our mission have inspired me since joining the company," added Bell.

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

Retrieved on: 
Friday, January 12, 2024

On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.

Key Points: 
  • On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.
  • GenScript Biotech is committed to building a high-quality platform for exchange and cooperation for global peers, driving the advancement of the cell and gene industry.
  • since the first global forum was held in 2020, GenScript Biotech has created numerous valuable opportunities for industry peers.
  • This grand event brought together the wisdom and strength of global elites in the biopharmaceutical industry, sparking a profound discourse on the future of GCT.

DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

Retrieved on: 
Tuesday, January 9, 2024

CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Bekhouche (Investment Corporation of Dubai) and Noubar Afeyan (Flagship Pioneering) to its Board of Directors. As a follow up to the company's initial financing announcement in September 2023, Indigo also announced the final close of its financing round at an expanded raise of nearly $270 million.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024.
  • Banks will also continue as an Indigo board member, a role he has held since July 2022.
  • Indigo also announced the appointments of Nader Bekhouche (Investment Corporation of Dubai) and Noubar Afeyan (Flagship Pioneering) to its Board of Directors.
  • "I'm thrilled to take on the role of CEO of Indigo Ag.